MARKET

ACST

ACST

Acasti Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7530
-0.0220
-2.84%
Opening 10:35 08/12 EDT
OPEN
0.7815
PREV CLOSE
0.7750
HIGH
0.7825
LOW
0.7500
VOLUME
466.45K
TURNOVER
--
52 WEEK HIGH
3.080
52 WEEK LOW
0.2500
MARKET CAP
69.64M
P/E (TTM)
-2.4967
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACST stock price target is 3.617 with a high estimate of 6.98 and a low estimate of 1.052.

EPS

ACST News

More
Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020
LAVAL, Quebec, July 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (ome
GlobeNewswire · 07/31 11:55
Why Acasti Pharma's Stock Is Trading Higher Today
Benzinga · 07/06 19:37
Acasti Pharma shares are trading higher after B.Railey FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.
Benzinga · 07/06 17:43
B. Riley FBR Upgrades Acasti Pharma to Buy, Announces $2 Price Target
B. Riley FBR analyst Mayank Mamtani upgrades Acasti Pharma (NASDAQ:ACST) from Neutral to Buy and announces $2 price target.
Benzinga · 07/06 12:01
Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q4 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 06/30 00:08
Acasti Pharma Provides Fiscal 2020 Year-End Business Update
GlobeNewswire · 06/29 14:45
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
GlobeNewswire · 06/19 13:00
Acasti Pharma under pressure on diminished expectations for second pivotal CaPre study
Seeking Alpha - Article · 06/19 12:36

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+1.48%

Hot Stocks

Symbol
Price
%Change

About ACST

Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill oil derived mixture containing polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). CaPre is designed to reduce triglycerides while also potentially providing beneficial effects on low-density lipoprotein (LDL) cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with severe hypertriglyceridemia.
More

Webull offers kinds of Acasti Pharma Inc stock information, including NASDAQ:ACST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACST stock methods without spending real money on the virtual paper trading platform.